Hematology Frontier

Editor's Note: From June 12 to 15, 2025, the European Hematology Association (EHA) Annual Congress was held in Milan, Italy, bringing together top experts in the field of hematology from…

Editor's Note: At the 2025 European Hematology Association (EHA) Annual Congress, a dedicated guideline session was grandly held, bringing together top experts in the global hematology field. One of the…

Editor's Note: At the European Hematology Association (EHA) 2025 Annual Congress, the special session on Multiple Myeloma (MM) was filled to capacity. The core focus of the meeting was the…

Editor's Note: During the 2025 European Hematology Association (EHA) Annual Meeting, a session on the interpretation of the new Peripheral T-Cell Lymphoma (PTCL) guidelines drew significant attention. At this session,…

Editor's Note: In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around…

Editor's Note: In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Meeting was grandly held in Milan, Italy in a combination of online and offline formats. Professor Johanna…

Editor's Note: At the recent European Hematology Association (EHA) Annual Congress, a premier event held in Milan, Italy, top global experts in hematology convened to discuss cutting-edge diagnostic and therapeutic…

The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on "Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy." She systematically reviewed the century-long evolution of ITP from its initial recognition to modern treatment, and by focusing on cutting-edge research, she outlined a clear roadmap for the future of personalized, precision therapy.

Editor's Note: Recently, the European Hematology Association (EHA) released its highly anticipated "Management of Aggressive Large B-cell Lymphoma (LBCL) Guidelines," providing comprehensive and authoritative clinical guidance for this highly heterogeneous…

In the high summer of 2025, the highly anticipated European Hematology Association (EHA) Annual Meeting was convened, bringing together top global experts in hematologic oncology to discuss cutting-edge progress and future directions in the field. In the Chronic Lymphocytic Leukemia (CLL) session, Dr. Daisy Diaz, a postdoctoral fellow from MD Anderson Cancer Center in the United States, representing the team of her mentor, Professor Deepa Sampath, delivered an exceptional presentation titled "A Study on Transcriptional Reprogramming and Survival Co-dependencies Following Venetoclax Resistance in Chronic Lymphocytic Leukemia." This research systematically unveiled the complex resistance mechanisms in CLL after the failure of Venetoclax treatment and proposed an innovative solution based on Proteolysis-Targeting Chimera (PROTAC) technology, offering a highly promising new approach for clinically overcoming dual-drug resistance.